文献速递前列腺癌

前列腺癌预防试验风险计算器2.0在标准活检与MRI/US融合引导活检中表现相当

The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-02-21

本研究纳入2007年8月至2014年2月接受MRI及融合引导活检/系统活检的前瞻性队列595例男性,比较前列腺癌预防试验风险计算器2.0(PCPTRC)对系统活检与联合活检的预测效能。结果显示,系统活检与联合活检的受试者工作特征曲线下面积(AUC)相似(P=0.70),高级别癌的AUC亦无统计学差异(P=0.55)。结论认为,在MRI筛查人群中PCPTRC仍是准确分层前列腺癌风险的实用方法。

要点

  • 595例男性中,系统活检检出前列腺癌39%(232例),联合融合引导/系统活检检出48%(287例)。
  • 系统活检与联合活检的AUC分别为0.69和0.70,差异无统计学意义(P=0.70)。
  • 高级别癌(Gleason≥7)的系统活检与联合活检AUC分别为0.71和0.70,差异无统计学意义(P=0.55)。

核心结论

  • 在MRI筛查后接受融合引导活检的男性人群中,PCPTRC仍是准确分层前列腺癌风险的实用方法。

研究设计与样本

  • 对2007年8月至2014年2月连续接受MRI及融合引导活检/系统活检的前瞻性队列进行回顾性分析,使用PCPTRC2.0R代码计算PCPTRC评分,共纳入595例男性。

主要发现

  • 系统活检检出前列腺癌39%(232例),联合融合引导/系统活检检出48%(287例)。
  • 系统活检与联合活检的AUC分别为0.69和0.70,差异无统计学意义(P=0.70)。
  • 高级别癌(Gleason≥7)的系统活检与联合活检AUC分别为0.71和0.70,差异无统计学意义(P=0.55)。

关键数值与推荐

  • PCPTRC对系统活检和联合活检的AUC分别为0.69和0.70(P=0.70)。
  • PCPTRC对高级别癌的系统活检和联合活检AUC分别为0.71和0.70(P=0.55)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC) is a widely used risk-based calculator used to assess a man's risk of prostate cancer (PCa) before biopsy. This risk calculator was created from data of a patient cohort undergoing a 6-core sextant biopsy, and subsequently validated in men undergoing 12-core systematic biopsy (SBx). The accuracy of the PCPTRC has not been studied in patients undergoing magnetic resonance imaging/ultrasound (MRI/US) fusion-guided biopsy (FBx). We sought to assess the performance of the PCPTRC for straitifying PCa risk in a FBx cohort. METHODS: A review of a prospective cohort undergoing MRI and FBx/SBx was conducted. Data from consecutive FBx/SBx were collected between August 2007 and February 2014, and PCPTRC scores using the PCPTRC2.0R-code were calculated. The risk of positive biopsy and high-grade cancer (Gleason ⩾7) on biopsy was calculated and compared with overall and high-grade cancer detection rates (CDRs). Receiver operating characteristic curves were generated and the areas under the curves (AUCs) were compared using DeLong's test. RESULTS: Of 595 men included in the study, PCa was detected in 39% (232) by SBx compared with 48% (287) on combined FBx/SBx biopsy. The PCPTRC AUCs for the CDR were similar (P=0.70) for SBx (0.69) and combined biopsy (0.70). For high-grade disease, AUCs for SBx (0.71) and combined biopsy (0.70) were slightly higher, but were not statistically different (P=0.55). CONCLUSIONS: In an MRI-screened population of men undergoing FBx, PCPTRC continues to represent a practical method of accurately stratifying PCa risk.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Maruf M, Fascelli M, George AK, et al. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis. 2017. PMID: 28220802. doi:10.1038/pcan.2016.46

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。